Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoCyte Corporation (trading symbol: OCX) on April 24, 2020. The registrant is a California corporation focused on molecular diagnostics. The report details a registered direct offering of common stock entered into on the date of the report.
Key Financial Metrics and Transaction Details
- Capital Raised: Approximately $10.75 million aggregate purchase price.
- Shares Issued: Up to 4,733,700 shares of common stock.
- Offering Price: $2.27 per share (based on the closing price on April 23, 2020).
- Transaction Costs: No fees, commissions, underwriting fees, or finder's fees were paid. No stock purchase warrants were issued.
- Investors: Selected investors including Broadwood Partners, L.P. (largest shareholder) and funds managed by Pura Vida Investments LLC.
- Use of Proceeds: Development and commercialization of DetermaRx, DetermaDx, and Insight Assays (Immuno-Oncology and triple negative breast cancer tests); clinical studies for reimbursement; future product development; general corporate purposes; and potential acquisitions (specifically the pending acquisition of Razor Genomics, Inc.).
Material Changes and Outlook
The filing does not provide comparative financial metrics (revenue, profit, cash flow, or margins) for the current period versus prior periods as this is a transactional report rather than a periodic financial statement. The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of new shares.
Outlook and Management Commentary: Management intends to utilize the net proceeds to advance clinical studies to support reimbursement and adoption of their diagnostic tests. The company also noted potential use of funds for strategic acquisitions, though no binding agreements exist other than the previously disclosed agreement regarding Razor Genomics.
Risks and Contingencies: The report includes standard forward-looking statement disclaimers. Actual results may differ due to risks outlined in the company's Form 10-K. The closing of the offering is subject to customary conditions and is expected during the week of April 27, 2020.
Investor Verification Checklist
- Verify the final closing date of the offering and the exact number of shares issued.
- Confirm the specific allocation of proceeds between clinical studies, product development, and the Razor Genomics acquisition.
- Review the full text of the Subscription Agreements (Exhibit 10.1) for specific covenants and termination provisions.
- Monitor the status of the Razor Genomics acquisition milestones and contingent considerations.
- Check subsequent filings for updates on the clinical progress of DetermaRx, DetermaDx, and Insight Assays.